The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
Journal Title
Future Oncology
Publication Type
Online publication before print
Abstract
Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be an appropriate alternative in selected patients. Thus, the NEOLETRIB trial evaluates the response of ER-positive, HER2-negative luminal A/B breast cancer to the combination of letrozole and ribociclib in the neoadjuvant setting. Comprehensive molecular biology procedures, including sequential single-cell RNA-sequencing of tumor biopsies, are performed during 6 months of treatment with extensive biobanking of blood samples, tumor biopsies and gut microbiome specimens. Our findings will hopefully contribute to an improved selection of patients who may benefit from this drug combination and give new insights into the intra-tumoral changes during this treatment.Trial registration number: NCT05163106 (ClinicalTrials.gov).; [Box: see text].; eng
Keywords
HR positive; gut microbiome; letrozole; locally advanced breast cancer; neoadjuvant; ribociclib; senescence; single-cell RNA sequencing
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1080/14796694.2024.2377531
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-08-29 04:13:42
Last Modified: 2024-08-29 04:22:13

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙